Use of MenACWY-CRM vaccine in 2- to 10-year-olds raised no safety concerns

 

Use of the MenACWY-CRM vaccine as part of routine clinical care of children aged 2-10 years does not appear to raise any safety concerns, reported Sara Yee Tartof, PhD, of Kaiser Permanente Southern California, Pasadena, and her associates.

CDC/Amanda Mills

Quadrivalent meningococcal conjugate vaccines prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135, and the U.S. Advisory Committee on Immunization Practices recommends vaccination for children aged 2-10 years of age who are at increased risk of meningococcal disease. MenACWY-CRM (Menveo) was approved by the U.S. Food and Drug Administration in January 2011 for use in that age group.

The study was undertaken to evaluate the safety of the MenACWY-CRM vaccine in the care of children aged 2-10 years in the real world. The other quadrivalent meningococcal conjugate vaccine, MenACWY-D (Menactra), was not used in this study.

In a retrospective, observational study of 327 children aged 2-10 years when they received the MenACWY-CRM vaccine as part of routine clinical care, there was only one event of interest, which was a child who developed asthma during the 1-year observation period, and that occurred 237 days after vaccination with both the MenACWY-CRM and a typhoid vaccine. “A causal link between the two events is unlikely,” Dr. Tartof and her associates wrote.

Most of the serious medically attended events were considered to be unrelated to MenACWY-CRM vaccination, or symptom onset occurred a long time after vaccination. “The remaining events were pneumonia, bronchitis, cough, febrile convulsion, and vomiting identified within 30 days of vaccination among four children,” the investigators reported. “Pneumonia, bronchitis, and cough were diagnosed in the same child; cough, febrile convulsion, and vomiting were diagnosed separately in the other 3 children.

“It appears that many MenACWY-CRM recipients in our study population received the vaccine because of travel to high-risk areas, possible exposure to meningitis, or as routine vaccinations received early as part of the ACIP-recommended routine vaccination for those 11-12 years old,” Dr. Tartof and her associates wrote.

Read more in the Pediatric Infectious Diseases Journal (2017 Nov 1. doi: 10.1097/INF.0000000000001696).

pdnews@frontlinemedcom.com

 

Use of the MenACWY-CRM vaccine as part of routine clinical care of children aged 2-10 years does not appear to raise any safety concerns, reported Sara Yee Tartof, PhD, of Kaiser Permanente Southern California, Pasadena, and her associates.

CDC/Amanda Mills

Quadrivalent meningococcal conjugate vaccines prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135, and the U.S. Advisory Committee on Immunization Practices recommends vaccination for children aged 2-10 years of age who are at increased risk of meningococcal disease. MenACWY-CRM (Menveo) was approved by the U.S. Food and Drug Administration in January 2011 for use in that age group.

The study was undertaken to evaluate the safety of the MenACWY-CRM vaccine in the care of children aged 2-10 years in the real world. The other quadrivalent meningococcal conjugate vaccine, MenACWY-D (Menactra), was not used in this study.

In a retrospective, observational study of 327 children aged 2-10 years when they received the MenACWY-CRM vaccine as part of routine clinical care, there was only one event of interest, which was a child who developed asthma during the 1-year observation period, and that occurred 237 days after vaccination with both the MenACWY-CRM and a typhoid vaccine. “A causal link between the two events is unlikely,” Dr. Tartof and her associates wrote.

Most of the serious medically attended events were considered to be unrelated to MenACWY-CRM vaccination, or symptom onset occurred a long time after vaccination. “The remaining events were pneumonia, bronchitis, cough, febrile convulsion, and vomiting identified within 30 days of vaccination among four children,” the investigators reported. “Pneumonia, bronchitis, and cough were diagnosed in the same child; cough, febrile convulsion, and vomiting were diagnosed separately in the other 3 children.

“It appears that many MenACWY-CRM recipients in our study population received the vaccine because of travel to high-risk areas, possible exposure to meningitis, or as routine vaccinations received early as part of the ACIP-recommended routine vaccination for those 11-12 years old,” Dr. Tartof and her associates wrote.

Read more in the Pediatric Infectious Diseases Journal (2017 Nov 1. doi: 10.1097/INF.0000000000001696).

pdnews@frontlinemedcom.com

 

Use of the MenACWY-CRM vaccine as part of routine clinical care of children aged 2-10 years does not appear to raise any safety concerns, reported Sara Yee Tartof, PhD, of Kaiser Permanente Southern California, Pasadena, and her associates.

CDC/Amanda Mills

Quadrivalent meningococcal conjugate vaccines prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135, and the U.S. Advisory Committee on Immunization Practices recommends vaccination for children aged 2-10 years of age who are at increased risk of meningococcal disease. MenACWY-CRM (Menveo) was approved by the U.S. Food and Drug Administration in January 2011 for use in that age group.

The study was undertaken to evaluate the safety of the MenACWY-CRM vaccine in the care of children aged 2-10 years in the real world. The other quadrivalent meningococcal conjugate vaccine, MenACWY-D (Menactra), was not used in this study.

In a retrospective, observational study of 327 children aged 2-10 years when they received the MenACWY-CRM vaccine as part of routine clinical care, there was only one event of interest, which was a child who developed asthma during the 1-year observation period, and that occurred 237 days after vaccination with both the MenACWY-CRM and a typhoid vaccine. “A causal link between the two events is unlikely,” Dr. Tartof and her associates wrote.

Most of the serious medically attended events were considered to be unrelated to MenACWY-CRM vaccination, or symptom onset occurred a long time after vaccination. “The remaining events were pneumonia, bronchitis, cough, febrile convulsion, and vomiting identified within 30 days of vaccination among four children,” the investigators reported. “Pneumonia, bronchitis, and cough were diagnosed in the same child; cough, febrile convulsion, and vomiting were diagnosed separately in the other 3 children.

“It appears that many MenACWY-CRM recipients in our study population received the vaccine because of travel to high-risk areas, possible exposure to meningitis, or as routine vaccinations received early as part of the ACIP-recommended routine vaccination for those 11-12 years old,” Dr. Tartof and her associates wrote.

Read more in the Pediatric Infectious Diseases Journal (2017 Nov 1. doi: 10.1097/INF.0000000000001696).

pdnews@frontlinemedcom.com